Probe: Alzheimer’s Drug Approval ‘Rife With Irregularities’

Probe: Alzheimer’s Drug Approval ‘Rife With Irregularities’
FILE - A sign for the Food and Drug Administration is displayed outside its offices in Silver Spring, Md., on Dec. 10, 2020. The FDA’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday, Dec. 29, 2022, as congressional investigators called the process “rife with irregularities.” (AP Photo/Manuel Balce Ceneta, File)

WASHINGTON (AP) — The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”

The 18-month investigation by two House committees detailed “atypical collaboration” between FDA regulators and a company it’s supposed to oversee — Aduhelm manufacturer Biogen. The probe also cited Biogen documents saying the company intended to “make history” when it set what investigators called an “unjustifiably high” initial price of $56,000 a year for the drug.

The criticism comes as the FDA is expected to decide whether to approve another new Alzheimer’s drug in January. Thursday’s report urged the agency to “take swift action” to ensure that any future Alzheimer’s approvals aren’t met with “the same doubts about the integrity of FDA’s review.”

The FDA and Biogen issued statements Thursday defending the Aduhelm approval process.

In 2021, the FDA overruled its own independent scientific advisers when it approved Aduhelm even though research studies failed to prove it really helped patients. Biogen had halted two studies after disappointing results suggested the drug wasn’t slowing Alzheimer’s inevitable worsening — only to later contend that a new analysis of one study showed higher doses offered an incremental benefit.

The FDA argued the drug’s ability to reduce a hallmark of Alzheimer’s, a buildup of plaque in the brain, suggested it was likely to slow the disease. Backlash was immediate as three FDA advisers resigned in protest and the agency’s then-acting chief called for an internal investigation. Eventually Medicare refused to pay for the drug — even after the yearly price was dropped to $28,000 — unless patients enrolled in clinical trials to prove if it indeed slowed cognitive decline.

Thursday’s report said FDA and Biogen engaged in an unusually high volume of phone calls, meetings and emails, some of them not properly documented. In addition, the regulators and company spent months working together to prepare a briefing document for FDA’s advisers that didn’t adequately represent substantial disagreement within the FDA about how to handle Aduhelm, the report said.

The investigators recommended that FDA take steps to restore trust in the approval process that include properly documenting interactions with drugmakers. They also urged manufacturers to take into account advice from patient groups and other outside experts on fair drug pricing.

In a statement Thursday, FDA said the Aduhelm decision “was based on our scientific evaluation of the data” and that the agency’s own internal review found its interactions with Biogen were appropriate. But it said it plans to update guidance on Alzheimer’s drug development and will review the investigation’s findings.

In its own statement, Biogen said: “Alzheimer’s is a highly complex disease and we have learned from the development and launch of Aduhelm” but that it “stands by the integrity of the actions we have taken.”

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

A+
a-
  • Biogen
  • FDA
  • In The News

    Health

    Voting

    Health

    April 25, 2025
    by Dan McCue
    Kennedy Unveils Plan to Expand Access to Sickle Cell Treatment

    CHARLESTON, S.C. — Health Secretary Robert F. Kennedy Jr. used a morning keynote address before a group of state lawmakers... Read More

    CHARLESTON, S.C. — Health Secretary Robert F. Kennedy Jr. used a morning keynote address before a group of state lawmakers in Charleston, South Carolina, to unveil a new initiative intended to expand access to the latest treatments for sickle cell disease. Kennedy offered few details in... Read More

    Whooping Cough Cases Rising Again in the US

    Whooping cough cases are rising, and doctors are bracing for yet another tough year. There have been 8,485 cases reported in... Read More

    Whooping cough cases are rising, and doctors are bracing for yet another tough year. There have been 8,485 cases reported in 2025, according to preliminary data from the U.S. Centers for Disease Control and Prevention. That’s twice as many cases as this time last year, based on the... Read More

    Bluebells and Other Spring Flowers Can Be Nature's Antidote to Stressful Times

    HALLE, Belgium (AP) — Gilles Gui was looking for the magical purple bluebells that raise their heads each spring under... Read More

    HALLE, Belgium (AP) — Gilles Gui was looking for the magical purple bluebells that raise their heads each spring under the budding beech leaves of the Hallerbos forest, an annual explosion of color that draws crowds from around the world. And in these times full of stress... Read More

    EPA Chief Demands That Mexico Stop Tijuana Sewage From Flowing Into California

    SAN DIEGO (AP) — The head of the Environmental Protection Agency said Tuesday that Mexico must stop the flow of billions of... Read More

    SAN DIEGO (AP) — The head of the Environmental Protection Agency said Tuesday that Mexico must stop the flow of billions of gallons of sewage and toxic chemicals from Tijuana that has polluted the Pacific Ocean off neighboring Southern California, closing beaches and sickening Navy SEALs who train... Read More

    April 22, 2025
    by Dan McCue
    FDA to Phase Out Petroleum-Based Dyes in Foods

    WASHINGTON — The Food and Drug Administration announced Tuesday that it plans to end the use of petroleum-based synthetic food... Read More

    WASHINGTON — The Food and Drug Administration announced Tuesday that it plans to end the use of petroleum-based synthetic food dyes in America’s food supply within the next two years in a bid to combat a myriad of health concerns, especially among children. The policy was... Read More

    Advanced Cancers Returned to Prepandemic Levels, According to Report

    Many Americans were forced to postpone cancer screenings — colonoscopies, mammograms and lung scans — for several months in 2020 as COVID-19... Read More

    Many Americans were forced to postpone cancer screenings — colonoscopies, mammograms and lung scans — for several months in 2020 as COVID-19 overwhelmed doctors and hospitals. But that delay in screening isn't making a huge impact on cancer statistics, at least none that can be seen yet by... Read More

    News From The Well
    scroll top